Spyre Therapeutics (SYRE) Debt to Equity: 2023-2025
Historic Debt to Equity for Spyre Therapeutics (SYRE) over the last 3 years, with Sep 2025 value amounting to $0.02.
- Spyre Therapeutics' Debt to Equity fell 67.96% to $0.02 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.02, marking a year-over-year decrease of 67.96%. This contributed to the annual value of $0.05 for FY2024, which is 541.21% up from last year.
- Per Spyre Therapeutics' latest filing, its Debt to Equity stood at $0.02 for Q3 2025, which was down 81.58% from $0.13 recorded in Q2 2025.
- In the past 5 years, Spyre Therapeutics' Debt to Equity ranged from a high of $0.13 in Q2 2025 and a low of -$0.79 during Q2 2023.
- Over the past 3 years, Spyre Therapeutics' median Debt to Equity value was $0.02 (recorded in 2024), while the average stood at -$0.04.
- The largest annual percentage gain for Spyre Therapeutics' Debt to Equity in the last 5 years was 1,763.77% (2025), contrasted with its biggest fall of 67.96% (2025).
- Spyre Therapeutics' Debt to Equity (Quarterly) stood at $0.01 in 2023, then spiked by 541.21% to $0.05 in 2024, then crashed by 67.96% to $0.02 in 2025.
- Its Debt to Equity stands at $0.02 for Q3 2025, versus $0.13 for Q2 2025 and $0.09 for Q1 2025.